Genmab — April 2025
-
slide 29 shows Current 2027 / 2028 market estimates for specific product sales -versus- internal forecast difference ~$1.8B / ~$2.3B : internal 2x higher , again this is for RYBREVANT / LAZCLUZE together https://s203.q4cdn.com/636242992/files/doc_financials/2025/q1/Final-JNJ-Earnings-Presentation-Q1-2025-Webcast.pdf
-
Genmab-partner overrasker positivt med salg af kræftmiddel https://proinvestor.com/investornyt/1303428/genmab-partner-overrasker-positivt-med-salg-af-kraeftmiddel
-
CURE Today
@cure_today
Tune into our video with Dr. Elizabeth K. Lee , of
@danafarber
, as she discusses treatment with with Rina-S; the agent showed antitumor activity in heavily pretreated patients with advanced OvarianCancer https://x.com/cure_today/status/1911917382366282044 -
-
Angående Sukkeralf 19.30.JNJs succes med Duobody taget i betragtning kan det måske godt blive interessant at høre, hvordan det ser ud med det fremadrettet hos JNJ. De har i øvrigt en fantastisk evne til så godt som aldrig at nævne Duobody og de har jo heller ikke flere licenser.
-
this is a Genmab Traverse partnership https://www.traversebiotech.com/pipeline https://www.prnewswire.com/news-releases/traverse-biotech-to-present-data-on-ror2-targeted-t-cell-engager-at-the-society-for-immunotherapy-of-cancers-sitc-39th-annual-meeting-302286375.html https://jitc.bmj.com/content/12/Suppl_2/A1185
-
Godmorgen
-
https://www.dnb.no/seg-fundamental/fundamentalweb/inst/GetReport.aspx?file=CMP4_255875.pdf&uid=1154&auth=2jMoUXPS1%2FJy8ZNikSg5XXKm0kY%3D&pwd=&popup=n DNB Markets - GENMAB
Looking beyond HexaBody-CD38 -
A case report of a heavily pretreated pt with DLBC post CART failure who was successfully treated with epcoritamab in community practice. https://x.com/mshadman/status/1912536749198438648
-
Godmorgen
-
small new trial by The Lymphoma Academic Research Organisation - Study of Epcoritamab in Relapsed and Refractory Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab (E-REVRI) https://clinicaltrials.gov/study/NCT06931652
-
EPCORE
CLL-1 adds 120 patients , for Treatment-naïve (TN) and high risk (HR) CLL https://clinicaltrials.gov/study/NCT04623541?tab=history&a=26&b=27&compareMode=sideBySide#version-content-panel
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind